---
schema_version: "secwatch.filing_event.v1"
accession: "0001217234-25-000036"
form_type: "8-K"
ticker: "CDNA"
cik: "0001217234"
company_name: "CareDx, Inc."
filed_at: "2025-04-30T23:59:59+00:00"
generated_at: "2026-05-23T02:02:02.101280+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# CareDx Q1 revenue $84.7M (+18% YoY); GAAP net loss narrows to $10.4M; non-GAAP net income $5.4M

## Summary
- Revenue $84.7M (+18% YoY); testing services revenue $61.9M (+15%), volume ~47,100 (+12% YoY).
- GAAP net loss $10.4M ($0.19 loss per share) vs $19.9M ($0.38) prior year; non-GAAP net income $5.4M ($0.09 diluted).
- Adjusted EBITDA $4.6M vs loss $1.9M; cash $231M, no debt.
- Reaffirms FY2025 revenue guidance $365-375M, adjusted EBITDA $29-33M; 2027 targets $500M rev, $100M EBITDA.
- Launched AlloSure Heart for pediatric and AlloSure Kidney for SPK; presented AlloHeme data at TANDEM and EBMT.

## SEC filing metadata
- accession: 0001217234-25-000036
- form_type: 8-K
- ticker: CDNA
- cik: 0001217234
- company_name: CareDx, Inc.
- filed_at: 2025-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1217234/000121723425000036/0001217234-25-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1217234/000121723425000036/cdna-20250430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001217234-25-000036
- JSON: https://secwatch.observer/filing/0001217234-25-000036.json
- Plain text: https://secwatch.observer/filing/0001217234-25-000036.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.